FDA To Extend Review Of Data Quality Submission For Genasense(R) In Melanoma

Genta Incorporated (Nasdaq: GNTA) announced that the Company has received notice from the Food and Drug Administration (FDA) that FDA has extended its review period of Genta’s request for correction of certain information that was filed pursuant to the Information Quality Act for an additional 60 days. [click link for full article]

More: continued here

Filed under: Cancer on December 24th, 2007